Welcome to our dedicated page for Aura Biosciences SEC filings (Ticker: AURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for Aura Biosciences, Inc. (NASDAQ: AURA), a Boston-based clinical-stage biotechnology company developing precision therapies for solid tumors that aim to preserve organ function. These regulatory documents provide detailed insight into AURA’s financial condition, clinical development plans, governance, and capital markets activity.
Among the most frequently referenced filings are Aura’s Form 10-K annual reports and Form 10-Q quarterly reports, which describe the company’s business, risk factors, research and development focus on bel-sar (AU-011), and operating expenses tied to its global Phase 3 CoMpass trial in early or early-stage choroidal melanoma, additional ocular oncology programs, and non-muscle invasive bladder cancer. Investors can also review Form 8-K current reports, such as those filed on dates when Aura announces quarterly results or updates its corporate presentation, to see how the company communicates material events and financial updates.
For users interested in ownership and governance, SEC filings provide information on matters submitted to stockholder votes, including director elections and auditor ratification, as illustrated by Aura’s Form 8-K reporting results of its annual meeting of stockholders. Registration statements and prospectus supplements related to public offerings of common stock and warrants detail how the company raises capital to fund its clinical programs and general corporate purposes.
Stock Titan’s platform enhances these filings with AI-powered summaries that highlight key points from lengthy reports, helping readers quickly understand clinical priorities, cash runway disclosures, and risk factor discussions without reading every page. Real-time updates from EDGAR ensure new AURA filings appear promptly, while structured access to forms such as 10-K, 10-Q, 8-K, and registration statements allows investors to navigate Aura Biosciences’ regulatory history efficiently.
Aura Biosciences, Inc. entered into a Repurchase Agreement with Matrix Capital Management Master Fund to buy back up to 6,922,870 shares of its common stock in a privately negotiated transaction. The repurchase price per share will match the price at which underwriters purchase shares in the company’s separately announced underwritten equity offering, which was set at $5.64 per share.
The company plans to fund the repurchase using a portion of net proceeds from the equity offering that exceed $200 million, after underwriting discounts and commissions. Matrix held approximately 10.8% of Aura’s outstanding common stock as of April 15, 2026. The stock repurchase is subject to the successful closing of the equity offering and other conditions and may not occur. Aura also disclosed preliminary cash, cash equivalents and marketable securities of about $114.7 million as of March 31, 2026, which are unaudited and subject to final accounting.
Aura Biosciences is offering shares of common stock and pre-funded warrants. The prospectus supplement states the company may use part of the net proceeds to repurchase up to 6,922,870 shares held by Matrix Capital Management Master Fund, LP, subject to completion and conditions.
The filing highlights clinical progress: the Phase 3 CoMpass trial of belzupacap sarotalocan (bel-sar) is nearing enrollment completion with 86 patients enrolled as of May 4, 2026, and topline data targeted for the second half of 2027. Preliminary cash and marketable securities were approximately $114.7 million as of March 31, 2026.
Aura Biosciences, Inc. has appointed industry veteran Natalie Holles as Chief Executive Officer, President and Class I director effective April 30, 2026, succeeding founder Elisabet de los Pinos, Ph.D., who is stepping down but will provide consulting services through October 30, 2026.
Holles’ package includes a $700,000 base salary, a target bonus of 55% of salary, and inducement equity equal to about 3% of Aura’s common stock and pre-funded warrants, split among options, RSUs and performance-based RSUs. Aura reported that its Phase 3 CoMpass trial of belzupacap sarotalocan in early choroidal melanoma has enrolled 86 patients, with more than 25 additional patients scheduled or identified, and reiterated guidance for enrollment completion by mid-2026 and topline data in the second half of 2027. The company also terminated its at-the-market prospectus after selling 1,055,362 shares for gross proceeds of about $6.7 million.
Aura Biosciences is asking stockholders to vote at its virtual 2026 annual meeting on June 11, 2026. Stockholders will elect two Class II directors, Teresa Marie Bitetti and David Johnson, to terms ending in 2029 and ratify Ernst & Young LLP as independent auditor for 2026.
Holders of 64,199,778 common shares as of April 15, 2026 may vote online, by phone, mail or during the webcast. The proxy also outlines governance practices, board structure and 2025 compensation, including total pay of $3.96 million for CEO Elisabet de los Pinos, Ph.D.
Aura Biosciences submitted a Form 144 notice reporting an insider sale of 12,079 shares of Common Stock on 02/17/2026. The filing also shows a 24,000 restricted stock unit award granted on 04/02/2024 and lists 64,150,468 shares outstanding as of 04/16/2026.
Aura Biosciences, Inc. insider Conor Kilroy reported an open-market sale of 11,738 shares of Common Stock at a weighted average price of about $7.02 per share. According to the disclosure, these shares were sold automatically to cover tax withholding obligations from vested restricted stock units, not at Kilroy’s discretion.
After the sale, Kilroy directly holds 217,835 Aura Biosciences shares, indicating that the transaction reflects a routine tax-related disposition rather than a change in his core ownership position.
Aura Biosciences files its annual report describing a clinical‑stage biotech focused on precision therapies for solid tumors, led by its virus‑like drug conjugate bel-sar.
Bel-sar is in a global Phase 3 trial for early choroidal melanoma and earlier trials showed 80% tumor control and 90% vision preservation in selected patients. The company is also developing bel-sar for metastases to the choroid and non‑muscle invasive bladder cancer, where early Phase 1 data showed local tumor responses and immune activation. Aura reports recurring losses, expects continued losses, and its auditors issued a “going concern” opinion, underscoring heavy dependence on future financings and on bel-sar’s clinical and regulatory success.
Aura Biosciences reported full-year 2025 results and updated its oncology pipeline. The company is advancing bel-sar, a virus-like drug conjugate, across ocular and urologic cancers. Its global Phase 3 CoMpass trial in early choroidal melanoma is enrolling faster than expected, with enrollment now targeted for completion by mid-2026 and topline data expected in the second half of 2027. A Phase 1b/2 trial in non-muscle-invasive bladder cancer is on track, with initial three-month data anticipated mid-2026, and multiple proof-of-concept ocular oncology studies are expected to read out in 2026.
As of December 31, 2025, Aura held $144.2 million in cash, cash equivalents and marketable securities and believes this will fund operations into the first quarter of 2027. Research and development expenses were $90.3 million for 2025, up from $73.3 million in 2024, reflecting progress of the Phase 3 melanoma trial and higher personnel costs. General and administrative expenses were $22.5 million, slightly below 2024 levels.
Net loss for 2025 was $106.2 million compared with $86.9 million in 2024, and basic and diluted net loss per share was $1.76 versus $1.75. Weighted average shares outstanding increased to about 60.3 million, driven by equity issuance and compensation. Management highlights bel-sar’s potential as a first-in-class, organ-preserving therapy across early choroidal melanoma, bladder cancer and other solid tumor indications, supported by favorable early safety and efficacy signals and multiple regulatory designations.
Kilroy Conor reported acquisition or exercise transactions in this Form 4 filing.
Aura Biosciences officer Conor Kilroy reported equity awards that increase his holdings. On March 2, 2026, he was granted a stock option for 112,661 shares of common stock at $0.00 per share and an award of 62,339 shares of common stock. The RSU shares vest in four equal annual installments starting January 15, 2027, while the option vests 25% on February 1, 2027 and the remainder in 36 monthly installments, all subject to continued service. After these grants, he directly owns 229,573 common shares and holds options for 112,661 shares.